{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/olecranon-bursitis/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"cdb27da7-1335-559d-9d4b-3fc3a0b6bc9b","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field 31174bdf-dd33-4fff-921f-8a3788ed7b5a --><h2>Clarithromycin</h2><!-- end field 31174bdf-dd33-4fff-921f-8a3788ed7b5a -->","summary":"","htmlStringContent":"<!-- begin item 95408f30-ea83-4f1b-b246-d0d3d013b477 --><!-- end item 95408f30-ea83-4f1b-b246-d0d3d013b477 -->","topic":{"id":"677058a2-327c-5c74-b020-fa294dc001d6","topicId":"2b5681b1-a6ac-486f-9c29-562f1d00c942","topicName":"Olecranon bursitis","slug":"olecranon-bursitis","lastRevised":"Last revised in January 2021","chapters":[{"id":"a4276506-6266-5cf4-a65d-b517b5e29073","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5f6379bf-0c3e-5f36-b626-ae14f093855a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"30dc5fe8-8e10-5195-be9c-2032a2fe9c29","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"606247ee-02bd-5fbb-ac4e-00181cb9d573","slug":"changes","fullItemName":"Changes"},{"id":"13cfdc08-b4d8-56a4-a5ac-0dfa1d7e6cfe","slug":"update","fullItemName":"Update"}]},{"id":"3f962ec9-103d-50a6-876c-4a47fb7de1c6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c7da3eeb-0643-5b34-ab2c-8ba9d3db1032","slug":"goals","fullItemName":"Goals"},{"id":"ce4821e2-3cc9-5e64-a68c-2347bb4c8b71","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d54ee925-bde2-5a23-a8d7-5890790b3298","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55611326-78d9-5af9-a3d8-3243f894aff6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"97a3cb4a-8ad1-5279-9a00-d3071c8afd3f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0ae95433-ad22-5338-aab8-270312eb6fa0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9d59d92b-a3ce-5a17-ad08-8bdcd5032439","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"198864d0-53c2-5b2c-b236-08be4dd0177d","slug":"definition","fullItemName":"Definition"},{"id":"1c159260-37b3-563a-831f-16da306c92e0","slug":"causes","fullItemName":"Causes"},{"id":"83714e1b-4423-54d1-893d-80c2a92a842a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e2b0682f-f14b-5991-9d25-9d0a5572ae36","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a6ff79ed-b8bd-5dde-b777-048ebe2f83e8","slug":"complications","fullItemName":"Complications"}]},{"id":"f4ab30bf-b462-5a3f-bf5c-a27ae9d3e6ff","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1d3747f8-bed3-50aa-9617-789459b5adf6","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"7ad7f12d-d8f0-59d8-8841-9ecbe656356c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"653f7410-1fe1-5ae6-a30f-00e9b38f6285","slug":"aspiration","fullItemName":"Aspiration"}]},{"id":"33abb1c3-d06d-580c-8e89-c9f79202fcdd","fullItemName":"Management","slug":"management","subChapters":[{"id":"8eafa19f-9b61-5217-a60d-8b7150c8d22e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"cd9798ba-7dc6-58f2-b485-1a83ce962077","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4cc6cfee-67bb-5942-a9b4-d95ff1d2b51a","slug":"analgesia","fullItemName":"Analgesia"},{"id":"0c0460df-e8f1-55c6-9812-ab8d4105711c","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"fa9d8342-ae93-5e02-bc7e-bc3667cbfbc9","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cdb27da7-1335-559d-9d4b-3fc3a0b6bc9b","slug":"clarithromycin","fullItemName":"Clarithromycin"}]},{"id":"004b3dea-95a9-59e3-8f0e-2c801e5ebb1a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"06e783b5-d47f-55ea-b7be-a3cbd73f4ddb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1fb7925d-db93-5872-9164-840da5cf1d91","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6a47a3d4-5551-565a-a0f6-618797e318a7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8a12dab5-123e-505b-bb29-69626a4ef54e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e3600086-ecd1-5ccd-9711-0f1444616612","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87436259-d98d-5e39-ba2d-28c6133751e5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5c35d7b1-2c5b-5fd5-9de1-d0a85c2d7931","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"cd9798ba-7dc6-58f2-b485-1a83ce962077","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"bafb0f40-0622-5a18-bfec-4885296eb304","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field eca83891-3eeb-47ad-a9e6-0458ff47476c --><h3>What are the contraindications and cautions for clarithromycin?</h3><!-- end field eca83891-3eeb-47ad-a9e6-0458ff47476c -->","summary":"","htmlStringContent":"<!-- begin item 815677f9-5990-426b-bd8a-41e5acda0ee4 --><!-- begin field 04e4051f-7be0-4f37-9085-781017cf1d06 --><ul><li><strong>Do not prescribe clarithromycin to people with:</strong><ul><li>A history of QT prolongation or ventricular cardiac arrhythmia, including Torsades de pointe arrhythmias.</li><li>Taking drugs that prolong the QT interval (for example haloperidol, sotalol, terfenadine, and pimozide) — macrolides can also prolong the QT interval, which is a risk factor for Torsades de pointes.</li><li>Hypokalaemia — due to the risk of prolongation of the QT interval.</li><li>Severe hepatic failure in combination with renal impairment.</li><li>Pregnancy or breastfeeding. Erythromycin is preferred in women who are pregnant or breastfeeding.</li></ul></li><li><strong>Prescribe clarithromycin with caution in people with:</strong><ul><li>Impaired hepatic function (or people concomitantly receiving potentially hepatotoxic drugs) — clarithromycin is principally excreted by the liver. Hepatic dysfunction including increased liver enzymes and cholestatic hepatitis (with or without jaundice) has been rarely reported with these drugs.</li><li>Renal impairment:<ul><li>For clarithromycin — use half the normal dose in severe renal impairment (eGFR less than 30mL/min) for a maximum duration of 14 days. Avoid Klaricid XL<sup>® </sup>(clarithromycin prolonged release once daily tablets) in people with eGFR less than 30 mL/min.</li></ul></li><li>Myasthenia gravis — macrolide antibiotics may aggravate the weakness of people with myasthenia gravis.</li><li>Conditions that predispose to QT interval prolongation.</li></ul></li><li><strong>Prescribe clarithromycin with caution in people with:</strong><ul><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (less than 50 beats per minute) — increased risk of QT prolongation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BNF 72, 2016</a>]</p><!-- end field 04e4051f-7be0-4f37-9085-781017cf1d06 --><!-- end item 815677f9-5990-426b-bd8a-41e5acda0ee4 -->","subChapters":[]},{"id":"5c68136c-dab8-5391-8672-6c95d4a1c1fe","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field dfd23635-57a1-4dfc-aa6d-a9612943cca5 --><h3>What are the drug interactions of clarithromycin?</h3><!-- end field dfd23635-57a1-4dfc-aa6d-a9612943cca5 -->","summary":"","htmlStringContent":"<!-- begin item 247570e5-6f87-4d63-beb1-be11a61838db --><!-- begin field 66e33967-ccc8-482b-be80-19ba6ca6af75 --><ul><li><strong>Drug interactions that may occur with clarithromycin include:</strong><ul><li><strong>Carbamazepine </strong>— macrolides inhibit the cytochrome P450 enzyme CYP3A4, resulting in reduced carbamazepine metabolism.<ul><li>Reduce the dose of carbamazepine by 30–50% during treatment with clarithromycin.</li><li>Advise the person to report symptoms of carbamazepine toxicity (such as dizziness, diplopia, ataxia, or confusion).</li></ul></li><li><strong>Warfarin </strong>— occasionally and unpredictably, the effects of warfarin may be markedly increased by macrolides.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) if a macrolide is taken with simvastatin or atorvastatin.<ul><li>For simvastatin — concurrent use with clarithromycin is contraindicated as simvastatin is extensively metabolized by CYP3A4. If treatment with clarithromycin cannot be avoided, stop treatment with simvastatin during the course of treatment.</li><li>For atorvastatin, avoid concurrent use with clarithromycin, as atorvastatin is moderately metabolised by CYP3A4. If concurrent use cannot be avoided, prescribe the lowest starting dose of atorvastatin (10 mg), and advise the person to report any muscle pain, tenderness, or weakness.</li><li>Clinically significant drug interactions resulting from cytochrome P450-mediated metabolism are not expected for rosuvastatin and pravastatin as they are not metabolized to a clinically significant extent by the cytochrome P450 system. Fluvastatin is not dependent on CYP3A metabolism; therefore, an interaction with clarithromycin is unlikely. Nevertheless, advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Calcium channel blockers (CCBs) </strong>— due to an increased risk of hypotension, caution is advised with the concurrent use of macrolides and CCBs metabolised by CYP3A4 (such as verapamil, amlodipine, and diltiazem).</li><li><strong>Oral hypoglycaemic drugs and insulin </strong>— the concomitant use of clarithromycin and oral hypoglycaemic drugs (such as sulphonylureas) and/or insulin can result in significant hypoglycaemia. <ul><li>Careful monitoring of blood glucose levels is recommended.</li></ul></li><li><strong>Drugs that prolong the QT interval </strong>(such as haloperidol, sotalol, terfenadine, and pimozide) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-2 agonists) — hypokalaemia is a risk factor for QT prolongation.<ul><li>Seek advice from a microbiologist regarding a suitable alternative antibiotic.</li></ul></li><li><strong>Oral hormonal contraception </strong>— additional contraceptive precautions are not required during or after courses of clarithromycin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">Preston, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BNF 72, 2016</a>]</p><!-- end field 66e33967-ccc8-482b-be80-19ba6ca6af75 --><!-- end item 247570e5-6f87-4d63-beb1-be11a61838db -->","subChapters":[]},{"id":"c8866e1b-a726-5003-802f-bba0c9f3857a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 6bf778c9-01c1-4d1a-886d-3388ba0c7566 --><h3>What are the adverse effects of clarithromycin?</h3><!-- end field 6bf778c9-01c1-4d1a-886d-3388ba0c7566 -->","summary":"","htmlStringContent":"<!-- begin item 4801130e-42c1-416e-85e9-02ff460fca5f --><!-- begin field 50f0de35-24d1-4e58-be9e-80daf534c141 --><ul><li><strong>Nausea, vomiting, abdominal discomfort, and diarrhoea</strong> are the most common adverse effects of macrolides, and are more common with erythromycin than with clarithromycin.</li><li><strong>Consider pseudomembranous colitis</strong> if a person develops severe diarrhoea during or after treatment with a macrolide.<ul><li>Pseudomembranous colitis is an acute, exudative colitis caused by <em>Clostridium difficile</em>, a Gram-positive toxin-releasing bacillus. It often follows antibiotic treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Anaphylaxis</strong> is rarely associated with macrolides.</li><li><strong>Hepatotoxicity</strong> (including cholestatic jaundice) and rash have been reported following treatment with macrolides.</li><li><strong>Reversible hearing loss</strong> (sometimes with tinnitus) can occur after large doses of clarithromycin (1–2 g) or erythromycin (more than 4g).</li><li><strong>Other adverse effects reported rarely or very rarely include</strong> pancreatitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/olecranon-bursitis/references/\">BNF 72, 2016</a>]</p><!-- end field 50f0de35-24d1-4e58-be9e-80daf534c141 --><!-- end item 4801130e-42c1-416e-85e9-02ff460fca5f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}